OUR PORTFOLIO

Redcliffe Lifetech

1.2m

CUSTOMERS SERVED

1.1m

TESTS UNDERTAKEN

21 labs

NATIONWIDE

Redcliffe Lifetech is an affordable and convenient omni-channel diagnostics service operating across 14 cities in India. The company facilitates at-home diagnostics for more than 3500 medical tests through their network of 350 mobile phlebotomists, supported by 21 state-of-the-art labs and overseen by experienced pathologists.

The company also leverages its network of over 400 off-line collection centres to drive volumes to its labs. By offering tests that can be ordered via smartphones, with results delivered in 24-48 hours, Redcliffe makes it simple for emerging consumers to take charge of their health, reducing the burden of noncommunicable diseases.

India is experiencing a spike in noncommunicable diseases (NCDs), driven by increases in heart disease, cancers, diabetes and chronic respiratory disease. NCDs contribute to 65% of total deaths in the country, with estimates that this figure could rise to 73% in the next decade1.

Left unaddressed, it is estimated NCDs will cost India approximately US$ 3.55 trillion in economic losses by 20302. NCDs account for 40% of all hospital stays and approximately 37% of all recorded outpatient visits in the country3. The money to fund out-of-pocket expenses for treatment often comes from household savings and money borrowed from relatives4. Household spending on healthcare frequently diverts resources away other critical areas like education or day-to-day essentials5.

Founded by entrepreneur Dheeraj Jain, Redcliffe’s network of 350 phlebotomists and logistics staff spans 21 specialist labs across 14 cities and enables timely and accurate results to be sent to consumers within 24 to 48 hours of testing.

The company has built its pathology labs to international specifications, providing a reliable option for consumers in a highly fragmented market. It is estimated there are nearly 100,000 clinical labs operating in India, with the vast majority lacking sufficient accreditation and compliance10

LeapFrog is committed to supporting Redcliffe as it expands access to diagnostics for emerging consumers in India, and will work with the firm to support its goal of reaching over 500 million Indians in the next 5 years.

Industry

Healthcare

Region

India

The LeapFrog Difference

LeapFrog is committed to supporting Redcliffe as it expands access to diagnostics for emerging consumers in India, and will work with the firm to support its goal of reaching over 500 million Indians in the next 5 years.

Geographic expansion will be a key focus for the firm in the years ahead as it pushes into Tier II and Tier III cities and widens its network of laboratories. Capital from LeapFrog will help to support this pursuit and experience in the market will assist Redcliffe to identify the best locations to target.

Improving Redcliffe’s customer experience will also be a key focus for LeapFrog through its CX Launchpad team, which plans to help optimise customer acquisition and retention methods. To date, the majority of customer conversions and bookings are facilitated by an in-house call centre, and with further digitalisation it is possible to improve this experience. Upgrades of booking software to accommodate the high number of local dialects and languages spoken across the country will also increase the product’s relevance for consumers.

LeapFrog will support Redcliffe’s significant R&D efforts as it continues to search for new ways to lower costs and improve access. This includes enhancing its internally developed live temperature scanning product and supporting its efforts to deliver drone-based pathology sample collection.

Read more about the importance of diagnostics in curbing the spread of NCDs, especially in India, in our Redcliffe Lifetech Impact Note.

This deal is subject to closing in accordance with the transaction terms

Investing in Asia

Redcliffe Lifetech is one of a number of exciting investments LeapFrog has made across Asia. Read more about our work delivering profit with purpose in Asia.

LeapFrog Investments